Figure 2.
(a) Number of MI patients (age<80) with and without P2Y12 inhibitor in Sweden; and (b) Proportion of dual antoplatelet treated MI patients (age<80) receiving ticagrelor per health care region in Sweden.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.